Table 3.

Pharmacokinetic results of the SQIN-Furosemide PK/PD study

	C max (ng/mL)	T max (h)	AUClast (h*ng/mL)	AUC0-24 (h*ng/mL)	AUCinf (h*ng/mL)	t 1/2 (h)	Vz/F (L)	CL (mL/h)
SC furosemide 5-h infusion
n	18	18	18	18	18	18	18	18
Mean	2010	NC	13 000	13 000	13 100	3.71	34 200	6360
SD	391	NC	2510	2510	2550	0.68	11 600	1520
CV%	19.5	NC	19.3	19.3	19.4	18.4	34.0	23.8
Geometric mean	1970	NC	12 800	12 800	12 900	3.65	32 700	6220
Geometric CV%	20.7	NC	21.6	21.6	21.7	17.7	29.7	21.7
Min	1210	2.0	7800	7800	7850	2.58	21 300	4650
Median	1940	5.0	13 600	13 600	13 700	3.70	30 500	5820
Max	2690	5.75	17 000	17 000	17 200	5.57	68 200	10 200
IV furosemide bolus administration
n	18	18	18	18	18	18	18	18
Mean	13 800	NC	11 900	12 000	12 000	3.67	37 900	7180
SD	4100	NC	3380	3370	3400	1.25	19 900	2070
CV%	29.8	NC	28.3	28.2	28.3	34.2	52.5	28.9
Geometric mean	13 100	NC	11 500	11 500	11 600	3.47	34 600	6920
Geometric CV%	34.8	NC	28.6	28.4	28.5	35.6	42.4	28.5
Min	6180	0.03	6450	6480	6480	1.91	21 200	3770
Median	14 400	0.08	11 600	11 600	11 700	3.55	34 400	6870
Max	21 800	0.25	21 000	21 000	21 200	6.70	107 000	12 300

AUC, area under the curve; AUC_inf, plasma concentration to infinity; AUC_last, last measurable plasma concentration; CL, systemic clearance; C_max, the peak plasma concentration; CV, coefficient of variation; t_1/2, terminal phase elimination half-life; T_max, the time from time 0 (pre-dose) to the peak plasma concentration; and Vz/F, volume of distribution.